PDF(1309 KB)
血液净化在重症腺病毒肺炎患儿中的临床应用
杨梅雨, 张新萍, 曹建设, 周雄, 蔡姿丽, 康霞艳, 谢波, 刘颖, 贺杰, 肖政辉
中国当代儿科杂志 ›› 2020, Vol. 22 ›› Issue (10) : 1109-1113.
PDF(1309 KB)
PDF(1309 KB)
血液净化在重症腺病毒肺炎患儿中的临床应用
Clinical application of blood purification in treatment of severe adenovirus pneumonia
目的 探讨血液净化在救治重症腺病毒肺炎患儿中的作用。方法 将2019年2~6月行机械通气治疗的57例重症腺病毒肺炎患儿，根据是否进行血液净化分为净化组（n=22）和常规组（n=35）。收集两组患儿的临床指标，包括热程、机械通气时间、重症监护室（ICU）住院时间及病死率；净化组血液净化前及净化后48 h白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）水平，血液净化前及净化后6、12、24、48 h的每搏输出变异率（SVV）、胸腔液体水平（TFC）、氧合指数（P/F）、二氧化碳分压（PCO2）。结果 净化组热程、机械通气时间、ICU住院时间均要短于常规组（P < 0.05），两组病死率比较差异无统计学意义（P > 0.05）。净化组患儿血液净化后IL-6、TNF-α水平较血液净化前均下降（P < 0.05）。血液净化后12、24、48 h ，净化组患儿SVV、TFC均较血液净化前下降（P < 0.01）。血液净化后6、12、24、48 h，净化组患儿P/F值均较血液净化前上升，PCO2均较血液净化前下降（P < 0.01）。结论 血液净化对重症腺病毒肺炎治疗具有辅助作用，可有效改善患儿的临床症状，是重症腺病毒肺炎有潜力的治疗选择。
Objective To study the role of blood purification in the treatment of severe adenovirus pneumonia. Methods A total of 57 children with severe adenovirus pneumonia who underwent mechanical ventilation from February to June, 2019, were enrolled. According to whether blood purification was performed, they were divided into a purification group with 22 children and a conventional group with 35 children. Related clinical indices were collected, including duration of fever, duration of mechanical ventilation, length of stay in the intensive care unit (ICU), and mortality rate. The purification group was analyzed in terms of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) before blood purification and at 48 hours after blood purification, as well as stroke volume variation (SVV), thoracic fluid content (TFC), arterial partial pressure of oxygen/fraction of inhaled oxygen (P/F) value, and partial pressure of carbon dioxide (PCO2) before blood purification and at 6, 12, 24, and 48 hours after blood purification. Results Compared with the conventional group, the purification group had significantly shorter duration of fever, duration of mechanical ventilation, and length of stay in the ICU (P < 0.05), and there was no significant difference in the mortality rate between the two groups (P > 0.05). The purification group had significant reductions in IL-6 and TNF-α after blood purification, (P < 0.05) and significant reductions in SVV and TFC at 12, 24, and 48 hours after blood purification (P < 0.01), as well as a significant increase in P/F value and a significant reduction in PCO2 at 6, 12, 24, and 48 hours after blood purification (P < 0.01). Conclusions Blood purification as an auxiliary therapy can effectively improve the clinical symptoms of children with severe adenovirus pneumonia, and is thus an option for the treatment of severe adenovirus pneumonia in children.
[1] Jain S. Epidemiology of viral pneumonia[J]. Clin Chest Med, 2017, 38(1):1-9.
[2] Ruuskanen O, Lahti E, Jennings LC, et al. Viral pneumonia[J]. Lancet, 2011, 377(9773):1264-1275.
[3] 中华医学会儿科学分会呼吸学组, 《中华儿科杂志》编辑委员会. 儿童社区获得性肺炎管理指南(2013修订)(上)[J]. 中华儿科杂志, 2013, 51(10):745-752.
[4] 中华医学会儿科学分会呼吸学组, 《中华儿科杂志》编辑委员会. 儿童社区获得性肺炎管理指南(2013修订)(下)[J]. 中华儿科杂志, 2013, 51(11):856-862.
[5] 中华医学会儿科学分会急救学组, 中华医学会急诊医学分会儿科学组, 中国医师协会儿童重症医师分会. 儿童脓毒性休克(感染性休克)诊治专家共识(2015版)[J]. 中国小儿急救医学, 2015, 22(11):739-743.
[6] 噬血细胞综合征中国专家联盟, 中华医学会儿科学分会血液学组. 噬血细胞综合征诊治中国专家共识[J]. 中华医学杂志, 2018, 98(2):91-95.
[7] Yoon HY, Cho HH, Ryu YJ. Adenovirus pneumonia treated with cidofovir in an immunocompetent high school senior[J]. Respir Med Case Rep, 2019, 26:215-218.
[8] Kim SJ, Kim K, Park SB, et al. Outcomes of early administration of cidofovir in non-immunocompromised patients with severe adenovirus pneumonia[J]. PLoS One, 2015, 10(4):e0122642.
[9] Ganapathi L, Arnold A, Jones S, et al. Use of cidofovir in pediatric patients with adenovirus infection[J]. F1000Res, 2016, 5:758.
[10] Alobaidi R, Morgan C, Basu RK, et al. Association between fluid balance and outcomes in critically ill children:a systematic review and meta-analysis[J]. JAMA Pediatr, 2018, 172(3):257-268.
[11] Miklaszewska M, Korohoda P, Zachwieja K, et al. Factors affecting mortality in children requiring continuous renal replacement therapy in pediatric intensive care unit[J]. Adv Clin Exp Med, 2019, 28(5):615-623.
[12] Arikan AA, Zappitelli M, Goldstein SL, et al. Fluid overload is associated with impaired oxygenation and morbidity in critically ill children[J]. Pediatr Crit Care Med, 2012, 13(3):253-258.
[13] Ingelse SA, Wiegers HM, Calis JC, et al. Early fluid overload prolongs mechanical ventilation in children with viral-lower respiratory tract disease[J]. Pediatr Crit Care Med, 2017, 18(3):e106-e111.
[14] Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock[J]. Crit Care Med, 2017, 45(6):1061-1093.
[15] Zakariás D, Marics G, Kovács K, et al. Clinical application of the electric cardiometry based non-invasive ICON® hemodynamic monitor[J]. Orv Hetil, 2018, 159(44):1775-1781.
[16] Della Rocca G, Costa MG. Hemodynamic-volumetric monitoring[J]. Minerva Anestesiol, 2004, 70(4):229-232.
[17] Yi L, Liu Z, Qiao L, et al. Does stroke volume variation predict fluid responsiveness in children:a systematic review and meta-analysis[J]. PLoS One, 2017, 12(5):e0177590.
[18] van de Water JM, Mount BE, Chandra KM, et al. TFC (thoracic fluid content):a new parameter for assessment of changes in chest fluid volume[J]. Am Surg, 2005, 71(1):81-86.
[19] Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response[J]. Annu Rev Immunol, 2001, 19:65-91.
[20] Fu Y, Tang Z, Ye Z, et al. Human adenovirus type 7 infection causes a more severe disease than type 3[J]. BMC Infect Dis, 2019, 19(1):36.
[21] Nakamura H, Fujisawa T, Suga S, et al. Species differences in circulation and inflammatory responses in children with common respiratory adenovirus infections[J]. J Med Virol, 2018, 90(5):873-880.
[22] 中华人民共和国国家卫生健康委员会, 国家中医药管理局. 儿童腺病毒肺炎诊疗规范(2019年版)[J]. 中华临床感染病杂志, 2019, 12(3):161-166.
[23] Chen LX, Demirjian S, Udani SM, et al. Cytokine clearances in critically ill patients on continuous renal replacement therapy[J]. Blood Purif, 2018, 46(4):315-322.
[24] Park JT, Lee H, Kee YK, et al. High-dose versus conventional-dose continuous venovenous hemodiafiltration and patient and kidney survival and cytokine removal in sepsis-associated acute kidney injury:a randomized controlled trial[J]. Am J Kidney Dis, 2016, 68(4):599-608.
[25] Quinto BM, Iizuka IJ, Monte JC, et al. TNF-α depuration is a predictor of mortality in critically ill patients under continuous veno-venous hemodiafiltration treatment[J]. Cytokine, 2015, 71(2):255-260.
